Corticotropin-Releasing Hormone (CRH) mRNA Expression in Rat Central Amygdala in Cannabinoid Tolerance and Withdrawal: Evidence for an Allostatic Shift?

33Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chronic treatment with cannabinoid agonists leads to tolerance. One possible mechanism for this is receptor internalization, but tolerance has also been reported with compounds that only cause internalization to a low degree. Furthermore, cannabinoid antagonist administration precipitates a characteristic withdrawal syndrome in tolerant subjects, accompanied by neuronal activation and enhanced release of corticotropin-releasing hormone (CRH) in the central amygdala. The underlying molecular mechanisms are unknown. We examined the role of cannabinoid tolerance and withdrawal for the expression of the cannabinoid 1 (CB1) receptor and of CRH in rats. Tolerance was first established functionally. An acute dose (100 μg/kg) of the CB1 agonist HU-210 suppressed locomotor activity, and had an anxiogenic-like effect on the elevated plus-maze. Both effects were absent following daily treatment with the same agonist or a lower (40 μg/kg) dose for 14 days. Next, withdrawal was reliably precipitated by a single dose (3mg/kg) of the CB1 antagonist SR141716A in rats treated subchronically with 14-day HU-210. Using in situ hybridization, a robust suppression of CB1 mRNA expression was found in the caudate-putamen, indicating a downregulation of CB1 expression levels as one mechanism for tolerance to the locomotor suppressant effects of HU-210. The CRH transcript was upregulated in the central amygdala in precipitated withdrawal compared to nonwithdrawn tolerant subjects, suggesting that increased gene expression contributes to the previously reported CRH release in withdrawal. Most importantly, this increase occurred from a suppressed level in tolerant subjects, and behavioral signs of withdrawal, presumably mediated by CRH, were seen at the CRH expression that had only returned to normal nontolerant levels. This suggests the possibility of an allostatic shift, as previously proposed on theoretical grounds. The expression of CRH-R1, CRH-R2α, NPY, and its Y1 receptor mRNA was analyzed in search of neural substrates for the allostatic shift observed, but did not seem to contribute to the dysregulated state.

References Powered by Scopus

Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

4942Citations
N/AReaders
Get full text

Drug addiction, dysregulation of reward, and allostasis

2355Citations
N/AReaders
Get full text

Cannabinoid receptor localization in brain

2072Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Obesity and addiction: Neurobiological overlaps

599Citations
N/AReaders
Get full text

Keep off the grass? Cannabis, cognition and addiction

294Citations
N/AReaders
Get full text

Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure

277Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Caberlotto, L., Rimondini, R., Hansson, A., Eriksson, S., & Heilig, M. (2004). Corticotropin-Releasing Hormone (CRH) mRNA Expression in Rat Central Amygdala in Cannabinoid Tolerance and Withdrawal: Evidence for an Allostatic Shift? Neuropsychopharmacology, 29(1), 15–22. https://doi.org/10.1038/sj.npp.1300296

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 26

44%

Researcher 18

31%

Professor / Associate Prof. 14

24%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 24

39%

Neuroscience 13

21%

Medicine and Dentistry 13

21%

Psychology 12

19%

Save time finding and organizing research with Mendeley

Sign up for free